This Article Full Text Full Text (PDF) Other Versions of this Article: IAI.00005-08v1 76/8/3801    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Google Scholar Articles by Steeghs, L. Articles by van Putten, J. P. M. PubMed PubMed Citation Articles by Steeghs, L. Articles by van Putten, J. P. M.

 Previous Article  |  Next Article 

Infection and Immunity, August 2008, p. 3801-3807, Vol. 76, No. 8
0019-9567/08/$08.00+0     doi:10.1128/IAI.00005-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Differential Activation of Human and Mouse Toll-Like Receptor 4 by the Adjuvant Candidate LpxL1 of Neisseria meningitidis

Department of Infectious Diseases and Immunology, University of Utrecht, Utrecht, The Netherlands,¹ Immunobiology and Infectious Disease and Microbiology Units, Institute of Child Health, UCL, London, United Kingdom,² Unit Research and Development, Netherlands Vaccine Institute, Bilthoven, The Netherlands³

Received 3 January 2008/ Returned for modification 29 January 2008/ Accepted 14 May 2008

Neisseria meningitidis LpxL1 lipopolysaccharide (LPS) bearing penta-acylated lipid A is considered a promising adjuvant candidate for inclusion in future N. meningitidis vaccines, as it elicits a markedly reduced endotoxic response in human macrophages relative to that in wild-type (hexa-acylated) LPS, while it is an equally effective adjuvant in mice. As dendritic cells (DC) and Toll-like receptors (TLR) are regarded as central mediators in the initiation of an immune response, here we evaluated the ability of LpxL1 LPS to mature and to activate human DC and examined its TLR4-/MD-2-activating properties. Unexpectedly, purified LpxL1 LPS displayed minimal human DC-stimulating properties compared to wild-type LPS. Although whole bacteria induced DC maturation and activation irrespective of their type of LPS, the LpxL1 mutant failed to activate the human recombinant TLR4/MD-2 complex expressed in HeLa cells. Similarly, purified LpxL1 LPS was unable to activate human TLR4/MD-2 and it even acted as an antagonist of wild-type LPS. Both wild-type and LpxL1 LPSs activated the murine TLR4/MD-2 complex, consistent with their abilities to induce maturation and activation of murine DC. Assays with cells transfected with different combinations of human and murine TLR4 and MD-2 indicated that TLR4 was a more-major determinant of the LPS response than MD-2. The species-specific activation of the TLR4/MD-2 complex by LpxL1 LPS may have an impact on the use of LpxL1 LPS as an adjuvant and the use of murine immunization models in human meningococcal vaccine development.

Published ahead of print on 19 May 2008.

Editor: B. A. McCormick

This article has been cited by other articles:

• Keestra, A. M., van Putten, J. P. M. (2008). Unique Properties of the Chicken TLR4/MD-2 Complex: Selective Lipopolysaccharide Activation of the MyD88-Dependent Pathway. J. Immunol. 181: 4354-4362 [Abstract] [Full Text]